- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06118983
Mejora de las transiciones y los resultados para los pacientes con insuficiencia cardíaca en la atención médica domiciliaria (I-TRANSFER-HF): un ensayo híbrido de implementación y eficacia de tipo 1
This study is trying to improve the hospital-to-home transition for people with heart failure who receive home care services. The study will test an intervention called I-TRANSFER-HF, which differs from usual care by combining early home health nurse visits and outpatient medical appointments.
The study is interested in two questions:
- Is I-TRANSFER-HF better than usual care at preventing heart failure patients from returning to the hospital within 30 days?
- Are there parts of I-TRANSFER-HF that are easy or hard to implement in the real world?
The researchers will answer these questions by testing the intervention among pairs of hospitals and home health agencies across the country. During the study, the hospital-agency pairs will be asked to implement I-TRANSFER-HF. The researchers will then compare the results from before and after I-TRANSFER-HF was adopted. They will also interview people from these hospitals and agencies to see how I-TRANSFER-HF is being implemented under real-world conditions.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The investigators' will test two hypotheses:
Hypothesis 1 (H1): Compared to usual care, adults with heart failure who receive the I-TRANSFER-HF intervention will have fewer 30-day readmissions, ED visits, and greater days at home. The four hospital-agency pairs will all begin the study with a baseline period of no intervention and then randomly selected to start the intervention phase at different points in time. Medicare claims data from each hospital-agency pair will be used to determine outcomes, and these data will be supplemented with national claims data for external controls not in the study to test the effectiveness of the I-TRANSFER-HF intervention.
Hypothesis 2 (H2): Compared to usual care, heart failure patients who receive I-TRANSFER-HF will have a higher proportion of timely first week HHC nursing visits (within 2 days of hospital discharge, plus 2 more) and outpatient visits (within 7-days of discharge). Given the rise of telemedicine, the study will test the association between the type of outpatient visit (in-person vs. virtual), its timing, and its association with outcomes. H2 requires conducting qualitative interviews with key stakeholders across the 4 hospital-agency pairs to identify barriers and facilitators that influence I-TRANSFER-HF's implementation. The study will assess the intervention's acceptability, feasibility, fidelity, and adaptation with interviews and Medicare claims data using a multi-methods approach and guided by the updated Consolidated Framework for Implementation Research (CFIR 2.0).
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Madeline R Sterling, MD, MPH, MS
- Número de teléfono: 6469625029
- Correo electrónico: mrs9012@med.cornell.edu
Ubicaciones de estudio
-
-
New York
-
New York, New York, Estados Unidos, 10021
- Reclutamiento
- Weill Cornell Medicine
-
Contacto:
- Madeline R Sterling, MD, MPH, MS
- Número de teléfono: 646-962-5029
- Correo electrónico: mrs9012@med.cornell.edu
-
Investigador principal:
- Madeline R Sterling, MD, MPH, MS
-
New York, New York, Estados Unidos, 10017
- Reclutamiento
- VNS Health Partners in Care
-
Contacto:
- Kathy Bowles, PhD, RN,FAAN
- Correo electrónico: bowles@nursing.upenn.edu
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Aim 1, Inclusion Criteria:
- Adults hospitalized for HF who transition from participating hospitals to their partner HHC agency during the study period.
Aim 1, Exclusion Criteria:
- Patients hospitalized for HF and discharged: home without HHC, or to an inpatient rehabilitation facility, skilled nursing facility, or hospice; patients with end stage renal disease on dialysis and those with left ventricular devices.
Aim 2, Inclusion Criteria:
- Healthcare professional involved in the transition of heart failure patients from the acute care setting (hospital) to HHC (home health care) agencies, and the implementation of the I-TRANSFER-HF at one of the four participating hospital-HHC dyads.
Aim 2, Exclusion Criteria:
- Healthcare professional not involved in the transition of heart failure patients from the acute care setting (hospital) to HHC (home health care) agencies, and the implementation of the I-TRANSFER-HF at one of the four participating hospital-HHC dyads.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Investigación de servicios de salud
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: I-TRANSFER-HF
This is a 1-year long intervention period when I-TRANSFER-HF is in operation. |
I-TRANSFER-HF is comprised of early and intensive HHC nurse visits and an outpatient visit within 7 days of discharge. Using a Hybrid Type 1, stepped wedge randomized trial design, we will test the effectiveness and implementation of I-TRANSFER-HF in partnership with 4 geographically diverse dyads of hospitals and HHC agencies ("hospital-HHC agency" dyads) across the US. |
|
Sin intervención: Standard of Care (usual care)
This is a baseline period of usual care (UC) with no intervention. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
All-cause 30-day hospital readmission
Periodo de tiempo: 30 days following post-Index HF Hospitalization
|
All-cause 30-day hospital readmission among adults hospitalized for heart failure who receive home health care after discharge and receive the I-TRANSFER-HF protocol compared to usual care, as assessed by Medicare claims |
30 days following post-Index HF Hospitalization
|
|
Number of Eligible patients
Periodo de tiempo: 12 months
|
Number of heart failure patients eligible to receive I-TRANSFER-HF as assessed by Medicare claims data |
12 months
|
|
Number of Eligible Patients Who Received Protocol Components
Periodo de tiempo: 12 months
|
Number of heart failure patients who received both components of I-TRANSFER-HF (front-loaded home health nurse visits and early outpatient medical follow-up), one, or none as assessed by Medicare claims data |
12 months
|
|
Modality of outpatient follow-up
Periodo de tiempo: 12 months
|
The modality of outpatient follow-up received (in-person vs. virtual visit) as assessed by Medicare claims data |
12 months
|
|
Timeliness of Post-Hospital Discharge Home Health Nursing Evaluation
Periodo de tiempo: 12 months
|
The timeliness of first-week nursing visits within 2 days of hospital discharge as assessed by Medicare claims data |
12 months
|
|
Timeliness of Post-Hospital Outpatient Follow-Up
Periodo de tiempo: 12 months
|
The timeliness of outpatient visits within 7 days of hospital discharge as assessed by Medicare claims data |
12 months
|
|
Feasibility of implementing I-TRANSFER-HF (Qualitative Interviews)
Periodo de tiempo: 30 days after intervention (year of intervention)
|
Feasibility will be assessed through qualitative interviews with site stakeholders |
30 days after intervention (year of intervention)
|
|
Feasibility of implementing I-TRANSFER-HF (Surveys)
Periodo de tiempo: 30 days after intervention (year of intervention)
|
Feasibility will be measured through the completion of the validated, 4-item, Feasibility of Intervention Measure (FIM). Items are measured on a 5-point Likert scale (Completely Disagree-Completely Agree). The score is calculated as the mean. The scale for this measure ranges from 4-20 with higher scores indicating greater perceived feasibility of the intervention. |
30 days after intervention (year of intervention)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
All-cause 30-day ED visits
Periodo de tiempo: 30 days following post-Index heart failure Hospitalization.
|
All-cause 30-day emergency department visits among adults hospitalized for heart failure who receive home health care after discharge and receive the I-TRANSFER-HF protocol compared to usual care, as assessed by Medicare claims data |
30 days following post-Index heart failure Hospitalization.
|
|
Days at home among adults hospitalized for heart failure who receive home health care after discharge and receive the I-TRANSFER-HF protocol compared to usual care, as assessed by Medicare claims
Periodo de tiempo: During a 12-month period (year of intervention)
|
Days at home will be calculated as 365 days minus the number of inpatient days in an acute care facility, an inpatient rehabilitation facility, a skilled nursing facility, or an inpatient hospice unit. |
During a 12-month period (year of intervention)
|
|
Acceptability of I-TRANSFER-HF - Qualitative Interviews
Periodo de tiempo: 30 days after intervention (year of intervention)
|
Acceptability will be assessed through qualitative interviews. |
30 days after intervention (year of intervention)
|
|
Acceptability of Intervention Measure for the I-TRANSFER-HF Study - Survey
Periodo de tiempo: 30 days after intervention (year of intervention)
|
Acceptability will be assessed through the 4-item, validated, Acceptability of Intervention Measure (AIM). Items are measured on a 5-point Likert scale (Completely Disagree-Completely Agree). The score is calculated as the mean. The scale for this measure ranges from 4-20 with higher scores indicating greater perceived acceptability of the intervention. |
30 days after intervention (year of intervention)
|
|
Fidelity of I-TRANSFER-HF (Participant-Completed)
Periodo de tiempo: 30 days after intervention (year of intervention)
|
Fidelity will be assessed by extent to which I-TRANSFER-HF is implemented by the study site teams. Fidelity will be measured using participant-completed fidelity checklists. These checklists will be developed during the implementation process. |
30 days after intervention (year of intervention)
|
|
Fidelity of I-TRANSFER-HF (Observational Ratings)
Periodo de tiempo: 30 days after intervention (year of intervention)
|
Fidelity will be assessed by extent to which I-TRANSFER-HF is implemented by the study site teams. Fidelity will be measured using observational fidelity ratings conducted by site champions. These checklists will be developed during the implementation process. |
30 days after intervention (year of intervention)
|
|
Adaptation of I-TRANSFER-HF
Periodo de tiempo: 30 days after intervention (year of intervention)
|
Adaptation will be assessed with qualitative interviews to document how the intervention was modified and refined during the study period. |
30 days after intervention (year of intervention)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Madeline R Sterling, MD, MPH, MS, Weill Medical College of Cornell University
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 23-06026204
- R01HL169312 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .